Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-01
2006-08-01
Kemmerer, Elizabeth (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C514S002600
Reexamination Certificate
active
07084119
ABSTRACT:
The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues; C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis. Moreover, the present invention relates to a therapeutic composition containing KGFdes1-23and a pharmaceutically acceptable carrier and the use thereof for wound healing purposes.
REFERENCES:
patent: 5654405 (1997-08-01), Rubin et al.
patent: 5665870 (1997-09-01), Rubin et al.
patent: 5677278 (1997-10-01), Gospodarowicz et al.
patent: 5707805 (1998-01-01), Rubin et al.
patent: 5731170 (1998-03-01), Rubin et al.
patent: 5741642 (1998-04-01), Rubin et al.
patent: 5773586 (1998-06-01), Gospodarowicz et al.
patent: 5814605 (1998-09-01), Pierce et al.
patent: 5824643 (1998-10-01), Pierce et al.
patent: 5843883 (1998-12-01), Gospodarowicz et al.
patent: 5863767 (1999-01-01), Gospodarowicz et al.
patent: 5965530 (1999-10-01), Pierce et al.
patent: 6074848 (2000-06-01), Gospodarowicz et al.
patent: 6420531 (2002-07-01), Rubin et al.
patent: 6677301 (2004-01-01), Gospodarowicz et al.
patent: WO 90/08771 (1990-08-01), None
patent: WO 96/11949 (1996-04-01), None
patent: WO 96/11951 (1996-04-01), None
Finch et al., Aug. 18, 1989 245:752-755.
Hsu et al., Mar. 1998, Prot. Expr. And Puri., 12:189-200.
Bare et al., Nov. 30, 1994 Biochem. Biophys. Res. Commun. 205:872-879.
Ron et al., 1993 Feb. 5, 1993 J. Biol. Chem., 268:2984-2988.
Rubin et al., Feb. 1989, proc. Natl. Acad. Sci., 86:802-806.
Nybo et al., Letter to the Editor “Mitogenic Activity of Keratinocyte Growth Factor Amino-Terminal Truncation Mutants: Deletion of Amino Acid Residues 1-15 Through 1-27”, In Vitro Cell Dev. Biol., Animal 33:606-607 (1997).
Rubin et al., “Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells”, Proc. Natl. Acad. Sci. USA, 86:802-806 (1989).
Bellosta et al.,J. Cell Biol. 121(3):705-713 (1993).
Bowie et al.Science247:1306-1310 (1990).
Curti., Crit. Rev. Oncology/Hematology 14:29-39 (1993).
Finch et al.,Science2:752-755 (1989).
Jain., Sci. Amer. 271:58-65 (1994).
Meyer-Ingold., TibTech 11:387-392 (1993).
Robinson, TibTech 10:1-2 (1992).
Ron et al.J. Biol Chem. 268:(4):2984-2988.
Baird et al., “Receptor-and Heparin-Binding Domains of Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 85:2324-2328 (1988).
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,”Anan. Rev. Biochem. 58:575-605 (1989).
Eriksson et al., “Three-Dimensional Structure of Human Basic Fibroblast Growth Factor,”Proc. Natl. Acad. Sci. U.S.A. 88:3441-3445 (1991).
Gospodarowicz et al., “Comparison of the Ability of Basic and Acidic Fibroblast Growth Factor to Stimulate the Proliferation of an Established Keratinocyte Cell Line: Modulation of Their Biological Effects by Heparin, Transforming Growth Factor β (TGFβ), and Epidermal Growth Factor (EGF),”Journal of Cellular Physiology142:325-333 (1990).
Harper and Lobb, “Reductive Methylation of Lysine Residues in Acidic Fibroblast Growth Factor: Effect on Mitogenic Activity and Heparin Affinity,”Biochemistry27:671-678 (1988).
Osslund et al., “Correlation Between the 1.6 Å Crystal Structure and Mutational Analysis of Keratinocyte Growth Factor,”Protein Science7:1681-1690 (1998).
Reich-Slotky et al., “Chimeric Molecules Between Keratinocyte Growth Factor and Basic Fibroblast Growth Factor Define Domains That Confer Receptor Binding Specificities,”The Journal of Biological Chemistry270(50):29813-29818 (1995).
Gospodarowicz Denis J.
Masiarz Frank R.
Chiron Corporation
Harbin Alisa A.
Kemmerer Elizabeth
Robins Roberta L.
Suh Young J.
LandOfFree
Truncated keratinocyte growth factor (KGF) having increased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated keratinocyte growth factor (KGF) having increased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated keratinocyte growth factor (KGF) having increased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676340